This article is more than 5 years old. Information may no longer be current.
Stage, tumor size predict survival in ovarian cancer
Click Here to Manage Email Alerts
Disease stage and tumor size can help predict whether patients with ovarian cancer will benefit more from neoadjuvant chemotherapy or primary surgery, according to study results published in the European Journal of Cancer.
The EORTC-55971 trial included 670 patients with ovarian cancer who were randomly assigned primary surgery or neoadjuvant chemotherapy. OS served as the primary endpoint.
Researchers also identified 10 baseline clinical and pathological characteristics to evaluate as potential predictive biomarkers that could guide treatment selection.
Overall, researchers found that largest metastatic tumor size (P=.008) and clinical stage (P=.016) were significantly associated with the magnitude of benefit from treatment in terms of 5-year survival.
Patients with stage IIIC disease and tumors ≤45 mm received greater benefit from primary surgery, whereas patients with stage IV disease and tumors >45 mm received greater benefit from neoadjuvant chemotherapy.
Patients with stage IIIC disease and large tumors, as well as patients with stage IV disease and smaller tumors, experienced similar outcomes regardless of treatment, researchers wrote.
“We estimated that, by selecting treatments for patients based on largest metastatic tumor and clinical stage, the potential 5-year survival rate in the population of treated patients would be 27.3% (95% CI, 21.9-33.0), [which is] 7.8% higher than if all were treated with primary surgery and 5.6% higher [than] if all were treated with neoadjuvant chemotherapy,” the researchers wrote.
Click Here to Manage Email Alerts